Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

6.985 +0.035 (+0.50%)
Streaming Delayed Price Updated: 1:54 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,274,367
Open 6.980
Bid (Size) 6.980 (14)
Ask (Size) 6.990 (73)
Prev. Close 6.950
Today's Range 6.810 - 7.045
52wk Range 5.570 - 11.46
Shares Outstanding 358,808,755
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
Why Bausch Health Companies Stock Dived by More Than 7% Today
A large red number on the bottom line attracted the wrong kind of investor attention for the company. 
Via The Motley Fool

Performance

YTD
-10.22%
-10.22%
1 Month
-24.57%
-24.57%
3 Month
-14.08%
-14.08%
6 Month
+2.12%
+2.12%
1 Year
+17.39%
+17.39%

More News

Read More
BHC Stock Earnings: Bausch Health Companies Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Bausch Health Companies Shares Are Falling After Q1 Results
Via Benzinga
Bausch Health Announces First Quarter 2024 Results
Via ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
Preview: Bausch Health Companies's Earnings
Via Benzinga
Salix Announces 2024 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Via ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Via ACCESSWIRE
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Via ACCESSWIRE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Via ACCESSWIRE
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Via ACCESSWIRE
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know
Via Benzinga
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Via ACCESSWIRE
A 'Toxic Byproduct of an Imperfect Higher Education System' — Famous Short Seller Known as 'The Assassin' Strikes Her Newest Target
Via Benzinga
Bausch Health Announces Board Refreshment
Via ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Via ACCESSWIRE
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Via ACCESSWIRE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.